|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1130 CONNECTICUT AVENUE, NW, #500 |
Address2 | |
City | WASHINGTON |
State | DC |
Zip Code | 20036 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 34502-12
|
||||||||
|
6. House ID# 335700000
|
TYPE OF REPORT | 8. Year | 2008 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Marra R Bussey, Associate, Corporate Government Affairs |
Date | 07/21/2008 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
H.R.2419, Farm, Nutrition, and Bioenergy Act of 2007; H.R.3161, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008; S.1859, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008.
Legislative proposals regarding national animal ID program and country of origin labeling: H.R.2419, Farm, Nutrition, and Bioenergy Act of 2007; H.R.3161, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008; S.1859, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
G. Lawrence |
Atkins |
|
|
|
Paul |
Ehrlich |
|
|
|
Robert |
Lively |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
H.R.1038, Access to Life-Saving Medicine Act; H.R.1908, Patent Reform Act of 2007; H.R.5629, Pathway for Biosimilars Act; S.316, Preserve Access to Affordable Generics Act; S.623, Access to Life-Saving Medicine Act; S.1082, Food and Drug Administration Revitalization Act; S.1145, Patent Reform Act of 2007; S.1505, Affordable Biologics for Consumers Act.
Legislative proposals effecting US patent system: H.R.1908, Patent Reform Act of 2007; S.1145, Patent Reform Act of 2007.
Legislative proposals regarding follow-on biologics: H.R.1038, Access to Life-Saving Medicine Act; H.R.5629, Pathway for Biosimilars Act; S.623, Access to Life-Saving Medicine Act; S.1082, Food and Drug Administration Revitalization Act; S.1505, Affordable Biologics for Consumers Act.
Legislative proposals regarding brand-generic drug firm agreements: S.316, Preserve Access to Affordable Generics Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
G. Lawrence |
Atkins |
|
|
|
Paul |
Ehrlich |
|
|
|
Robert |
Lively |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LBR
16. Specific lobbying issues
H.R.2, Fair Minimum Wage Act of 2007; H.R.976, Children's Health Insurance Program Reauthorization Act of 2007; H.R.1257, Shareholder Vote on Executive Compensation Act; H.R.4854, False Claims Act Correction Act of 2007; S.2401, False Claims Act Correction Act of 2007.
Legislative proposals regarding shareholder participation in corporate executive compensation decisons: H.R.2, Fair Minimum Wage Act of 2007; H.R.976, Children's Health Insurance Program Reauthorization Act of 2007; H.R.1257, Shareholder Vote on Executive Compensation Act.
Legislation to amend the Federal False Claims Act: H.R.4854, False Claims Act Correction Act of 2007; S.2401, False Claims Act Correction Act of 2007.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
G. Lawrence |
Atkins |
|
|
|
Paul |
Ehrlich |
|
|
|
Robert |
Lively |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R.1585, National Defense Authorization Act for Fiscal Year 2008; H.R.2638, Department of Homeland Security Appropriations Act, 2008; H.R.2900, Food and Drug Administration Amendments Act of 2007; H.R.3161, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008; H.R.3162, Children's Health and Medicare Protection Act of 2007; H.R.4083, Non-prescription Drug Modernization Act od 2007;
S.242, Pharmaceutical Market Access and Drug Safety Act of 2007; S.468, Food and Drug Administration Safety Act of 2007; S.484, Enhancing Drug Safety and Innovation Act of 2007; S.830, Pediatric Medical Device Safety and Improvement Act of 2007; S.993, Pediatric Research Improvement Act; S.1082, Food and Drug Administration Revitalization Act; S.1547, National Defense Authorization Act for Fiscal Year 2008; S.1859, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008; S.2331, Non-prescription Drug Modernization Act of 2007; SConRes.21, Concurrent resolution setting forth the congressional budget for the United States.
Legisaltive proposals to extend federal contract prices to the retail section in the TRICARE program: H.R.1585, National Defense Authorization Act for Fiscal Year 2008; S.1547, National Defense Authorization Act for Fiscal Year 2008.
Legilsative proposals permitting importation of prescription drugs from overseas: H.R.2638, Department of Homeland Security Appropriations Act, 2008; H.R.3161, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008; H.R.3162, Children's Health and Medicare Protection Act of 2007; S.242, Pharmaceutical Market Access and Drug Safety Act of 2007; S.1082, Food and Drug Administration Revitalization Act; S.1859, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008; SConRes.21, Concurrent resolution setting forth the congressional budget for the United States.
Legislative proposals regarding drug safety, clinical trial registries, DTC adverstising, and reauthorization of the Prescription Drug User Fee Act, Best Pharmaceuticals for Children Act and Pediatric Research Equity Act: H.R.2900, Food and Drug Administration Amendments Act of 2007; S.468, Food and Drug Administration Safety Act of 2007; S.484, Enhancing Drug Safety and Innovation Act of 2007; S.830, Pediatric Medical Device Safety and Improvement Act of 2007; S.993, Pediatric Research Improvement Act; S.1082, Food and Drug Administration Revitalization Act; S.1547, National Defense Authorization Act for Fiscal Year 2008.
Legislative proposals regarding FDA funding: H.R.3161, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008; S.1859, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008.
Legislative proposals to ensure access to meth-safe alternative medicines: H.R.3161, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008; S.1859, Agriculture, Rural Development , Food and Drug Administration, and Related Agencies Appropriations Act, 2008.
Legislative propsals to reform the OTC monograph system: H.R.4083, Non-prescription Drug Modernization Act of 2007; S.2331, Non-prescription Drug Modernization Act of 2007.
Response to congressional investigation regarding ENHANCE study.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
G. Lawrence |
Atkins |
|
|
|
Paul |
Ehrlich |
|
|
|
Robert |
Lively |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R.4, Medicare Prescription Drug Price Negotiation Act of 2007; H.R.3162, Children's Health and Medicare Protection Act of 2007; S.3, Medicare Prescription Drug Price Negotiation Act of 2007; S.250, Medicare Enhancements for Needed Drugs Act of 2007;
S.965,U.S. Troop Readiness, Veterans' Care, Katrina Recovery, and Iraq Accountability Appropriations Act, 2007; SConRes.21, Concurrent resolution setting forth the congressional budget for the United States.
Legislative proposals to repeal Medicare "non-interference" provisions: H.R.4, Medicare Prescription Drug Price Negotiation Act of 2007; S.3, Medicare Prescription Drug Price Negotiation Act of 2007; S.250, Medicare Enhancements for Needed Drugs Act of 2007; SConRes.21, Concurrent resolution setting forth the congressional budget for the United States.
Legislative proposals effecting Medicaid "average manufactureres' price" AMP: H.R.3162, Children's Health and Medicare Protection Act of 2007; S.965,U.S. Troop Readiness, Veterans' Care, Katrina Recovery, and Iraq Accountability Appropriations Act, 2007.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
G. Lawrence |
Atkins |
|
|
|
Paul |
Ehrlich |
|
|
|
Robert |
Lively |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |